India might approve Novavax in 2 months, likely to cost more than Covishield: CEO
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
February 04, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, FEBRUARY 04, 2023
India might approve Novavax in 2 months, likely to cost more than Covishield: CEO

Coronavirus chronicle

TBS Report
30 June, 2021, 07:05 pm
Last modified: 30 June, 2021, 07:09 pm

Related News

  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Adani crisis not going to be indicative of how well Indian financial markets governed: Finance minister
  • Russia in favour of India becoming permanent member of UNSC: Envoy
  • Indian police arrest 1,800 men in crackdown on underage marriage
  • Indian shares set to rise on easing inflation concerns; Adani stocks in focus

India might approve Novavax in 2 months, likely to cost more than Covishield: CEO

While Novavax has shown 90% effectiveness against Covid, more data is needed on whether it will protect against the Delta variant, a virulent and fast-spreading mutation that was detected in India and is driving fresh cases in parts of the world.

TBS Report
30 June, 2021, 07:05 pm
Last modified: 30 June, 2021, 07:09 pm
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

The Covovax shot developed by American vaccine-maker Novavax may be cleared for use in India between July and September, which would make it the fifth vaccine in the country. The vaccine would cost a "low single dollar" price per dose but is likely to be costlier than Covishield, the company's CEO said today in an interview.

Stanley Erck, the president and CEO of Novavax, also said that while Covovax is known to work on Covid variants, the data of its effectiveness against the Delta variant is not known yet, reports the NDTV.

"We have conducted clinical trials that show that the vaccine works extraordinarily well in phase 3 trials in the UK. And in the US we are in the last stages of preparing all of the clinical data, the safety data, and now the manufacturing data that has to go into a licensing package. Our expectation is that the package will be complete very soon, certainly in the coming quarter," Erck said.

While Novavax has shown 90% effectiveness against Covid, more data is needed on whether it will protect against the Delta variant, a virulent and fast-spreading mutation that was detected in India and is driving fresh cases in parts of the world.

"We have very high rates of efficacy when there are variant circulating, we had a 100% protection against moderate and severe disease, and we were 93% protective against the variants that were circulating in our US trial. What we did not show is anything that gets Delta because Delta was not circulating during our trial. So we don't have those data yet. So time will tell," said the CEO.

But he stressed that tests were on.

"What we hope, based upon the data that we have against a variety of variances, is that we will have a significant amount of efficacy against Delta. I just can't tell you what that number is yet, because we have not been in the trial where Delta has been circulated."

Besides India, approvals are expected around the same time in Europe and UK for the vaccine.

He admitted to a delay in regulatory approvals, blaming it on the fact that the company started the process a year ago without any manufacturing or process development capabilities.

"So while we were running and getting clinical efficacy data, clinical safety data, we were way behind on manufacturing data. So we had to run fast to build that capability. In part that's why we have partnered with Serum Institute - because they have those capabilities," said Erck.

Top News

Novavax Covid-19 Vaccine / India

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • The Adani Group headquarters in Ahmedabad. Photo: Bloomberg
    Adani Enterprises shelves $122 million bond plan
  • Photo: Joynal Abedin Shishir/TBS
    BNP calls for road march in all unions on 11 February
  • Illustration: TBS
    Cash-strapped banks fail to maintain emergency cash

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Adani crisis not going to be indicative of how well Indian financial markets governed: Finance minister
  • Russia in favour of India becoming permanent member of UNSC: Envoy
  • Indian police arrest 1,800 men in crackdown on underage marriage
  • Indian shares set to rise on easing inflation concerns; Adani stocks in focus

Features

Sketch: TBS

Say 'Salud' before your salad main course

8h | Food
Coots running. Photo: Enam Ul Haque

Cute Coot of Baikka Beel: 'And yet he was as bald as a coot'

2h | Panorama
With only one government run specialised cancer hospital in the capital — the National Institute Of Cancer Research and Hospital (NICRH) in Mohakhali — patients have no option but to resort to private hospitals. Photo: Noor A Alam.

Cancer care: Medical treatment and beyond

9h | Panorama
Andy Mukherjee. Sketch: TBS

What makes India's billionaires' support special for Adani

1d | Panorama

More Videos from TBS

Prioritise medical equipment, raw material imports over luxury items

Prioritise medical equipment, raw material imports over luxury items

13m | TBS Round Table
Concord launches new plant to produce environment friendly bricks

Concord launches new plant to produce environment friendly bricks

5h | TBS Stories
How Asif Khan would invest his fresh funds right now

How Asif Khan would invest his fresh funds right now

5h | TBS Markets
A proper price formula can help investors to plan big

A proper price formula can help investors to plan big

1d | TBS Round Table

Most Read

1
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

4
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]